Pfizer Inc. (NYSE:PFE) Q4 2025 Earnings Call Transcript February 3, 2026 Pfizer Inc. beats earnings expectations. Reported ...

BPC-157 hasn't been approved by the FDA. But that hasn't stopped this buzzy drug from gaining traction – and attention from MAHA.

Good day, everyone, and welcome to Pfizer's Fourth Quarter 2025 Earnings Conference Call. Today's call is being recorded. At ...

Anavex (AVXL) blarcamesine faces uncertain FDA path in early Alzheimer’s; Phase 3 may be needed. Read here a detailed ...

Debated is the genesis of the first direct-to-consumer (DTC) drug concept in the U.S. Going back to at least 2011, Pfizer’s “unorthodox” ...

Wegovy pills are now available in the U.S., offering a prescription-based, convenient alternative for weight management ...

The gray market is awash with BPC-157, a drug hyped as a cure-all, but unapproved by the FDA. Will RFK Jr. change that?

Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M ...

Carefully timed bursts of carbon dioxide are emerging as a surprising tool to help the brain wash away toxic proteins linked to Parkinson’s disease. Instead of a new pill or implant, researchers are ...

Bacteria incubated with bacteriophages in space accumulated distinct mutations compared to those on Earth, highlighting the ...

Albert Bourla: 2025 was a very good year for Pfizer Inc. I'm very pleased with strong execution to deliver and, frankly, overdeliver on our financial commitments. If successful, we will substantially ...

Novo Nordisk operates in the pharmaceutical sector, with core franchises in diabetes care and obesity care supported by a ...